Researchers Identify Glycan Fingerprint for Stomach Cancer Risk in H. pylori Patients

In a recent study published in Cancer Prevention Research, researchers identified a serum glycan that has the potential to serve a diagnostic tool that would differentiate between patients with gastric cancer and patients with non-atrophic gastritis.  

Advertisement

Of those that have a Helicobacter pylori infection, one to three percent develop stomach cancer. The serum glycan could serve to identify patterns that indicate an early biomarker of gastric cancer.

More Articles on Gastroenterology:
14 Colonoscopy Quality Indicators to Consider
ASGE Announces New 2014 Training Courses
10 Most-Read Stories on Gastroenterology

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.